Sutura Therapeutics Ltd
Edwin Wagena is the Chief Executive Officer at Sutura Therapeutics Ltd and also holds the title of Chief Operating Officer and Advisor. Edwin is involved in the integrated development of innovative therapies and technology platforms at TIC-T. Previously, Edwin served as the Chief Executive Officer at Atelerix Ltd, Chief Operating Officer at Rexgenero, Chief Development Officer at Kiadis Pharma, and held various scientific roles at Maastricht University and University Nijmegen. Edwin holds a Ph.D. from Maastricht University and a Master's Degree in Health Sciences from the University of Groningen.
Sutura Therapeutics Ltd
Sutura Therapeutics is a biopharmaceutical company at the forefront of developing next-generation biomolecular medicines. Through its innovative drug conjugate platform, Sutura is advancing the field of biomolecular medicine to address the unmet medical needs of patients with diseases which were previously considered undruggable. Biomolecule-based medicines have unique biological properties and actions, which make them promising in treating diseases. However, the size and shape of biomolecules often limit their capacity to enter cells and reach their target, making them less effective. Sutura’s drug conjugates platform is designed to overcome these limitations and has the potential to address a broad range of indications.